Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sun Pharma to Acquire Checkpoint Therapeutics. Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics announced an agreement for Sun Pharma to…
Sun Pharma has acquired all outstanding shares of Checkpoint at a price of $4.10 per share in cash, without interest, plus one non-tradable contingent value…
At ASCO 2026 (presented May 31, 2026) Sun Pharma reported laCSCC long-term follow-up: n=64, ORR 50% (CR 27%, PR 23%), median DOR not reached at >31 mo,…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
Sun Pharma agreed to acquire Checkpoint Therapeutics for $4.10/share cash plus CVR up to $0.70/share tied to EU approval milestones, total ~$355M. Deal brings UNLOXCYT, the first FDA-approved anti-PD-L1 treatment for advanced cSCC. Closed May 30, 2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. / Checkpoint Therapeutics, Inc. (this deal) | 2025 | $355M | — |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2014 | $4.0B | 66 |
| Sun Pharmaceutical Industries Ltd. / Ranbaxy Laboratories Limited | 2015 | $4.0B | 52 |
| Sun Pharmaceutical Industries Ltd. / DUSA Pharmaceuticals, Inc. | 2012 | $230M | 49 |
| Sun Pharmaceutical Industries Ltd. / URL Pharma, Inc. (generics business) | 2012 | $60M | 34 |
| Sun Pharmaceutical Industries Ltd. / Organon & Co. | 2026 | $11.8B | — |
| Ciba-Geigy AG / Sandoz AG | 1996 | $36.3B | 98 |
← Browse all deals · How we score deals
More: 2025 deals · Sun Pharmaceutical Industries Ltd. deals · Dermatology deals